37^th World Pharmacology and Therapeutics Forum October 25-26, 2021 Rome, Italy

Dr. Ralph Brückner has a strong interest for the interaction of chemistry with biological systems that has lead him through an exciting journey from Medicinal Chemistry to modern Hygiene. He has achieved his PHD at the university of Würzburg on the metabolic fate and neurotoxic behaviour of (14C)TaClo, an endogenously formed ß-carbolin. As post doc he moved to the research Center Jülich where he established one of the first hypenations of ion chromatography with mass spectrometry for the elucidation of Krebs-cyle metabolites in bacteria. From there he received a call to follow the new team of medicinal chemistry department of Boehringer Ingelheim in Vienna (Austria). As head of laboratory he was reponsible for PK/PD in the thrilling field of oncology for 8 years. Since 2016 he works within the HECOSOL GmbH as head of R&D on the development of antimicrobial surfaces in sensitive areas of the medical sector and the food industry. The intention is to reduce hospital acquired infection diseases by a permanent reduction of pathogenic germs.

ADME, Drug Discovery

Dr. Ralph Brückner has a strong interest for the interaction of chemistry with biological systems that has lead him through an exciting journey from Medicinal Chemistry to modern Hygiene. He has achieved his PHD at the university of Würzburg on the metabolic fate and neurotoxic behaviour of (14C)TaClo, an endogenously formed ß-carbolin. As post doc he moved to the research Center Jülich where he established one of the first hypenations of ion chromatography with mass spectrometry for the elucidation of Krebs-cyle metabolites in bacteria. From there he received a call to follow the new team of medicinal chemistry department of Boehringer Ingelheim in Vienna (Austria). As head of laboratory he was reponsible for PK/PD in the thrilling field of oncology for 8 years. Since 2016 he works within the HECOSOL GmbH as head of R&D on the development of antimicrobial surfaces in sensitive areas of the medical sector and the food industry. The intention is to reduce hospital acquired infection diseases by a permanent reduction of pathogenic germs.

ADME, Drug Discovery

Senior Clinical Operations Team Lead in global multi-regional trials responsible for resource management and clinical team performance, key performance indicatior adherence and overal study or program control. Clinical trial experience covers Phase II-IV trials in such fields as rheumatology, oncology, cardiology, pulmonology, neurology, endocrinology, infectious diseases and surgery

Global clinical trial management, Quality assurance

Biologist and pharmacologist , biochemist by training , with a Master in Science (Doctor in Biology) from the University of Florence, Italy , and a PhD in Pharmacology from the University of Toulouse, France, 1997, Cristina Cosi has an extensive working experience in the Neuroscience research field, mostly in industry at Pierre Fabre, France, but also in academic environments, in Italy , University of Florence and Verona, and US, NIH. She has focused her career on the understanding of neurodegenerative processes and mechanisms of neuronal plasticity in order to find medications that might be beneficial against neurodegenerative and neurodevelopmental diseases and pain. She has done pioneering work in the poly(ADP-ribose) polymerase (PARP) inhibitors preclinical research field, by showing evidence of the neuroprotective activity of these compounds, for the first time. She has contributed to the discovery and development of neurotrophins receptors TRKA/B inhibitors as potential analgesics and D3 antagonists/5-HT1A agonists as potential antipsychotics.

Pharmacology and Neuroscience